Crossmark

SF3B1 mutation as a predictive biomarker for luspatercept efficacy in myeloproliferative neoplasms and MDS/MPN: a clinical study

Published Online: 2026-01-16

Authors

Cui, Tingting

Gong, Jie

Zhang, Xinyu

Zhang, Juan

Wei, Na

Zheng, Wenqi

Duan, Minghui
License Information

Text and Data Mining valid from 2026-01-16

Version of Record valid from 2026-01-16
More Information

Article History

Received: 7 August 2025

Accepted: 13 November 2025

First Online: 16 January 2026

Declarations

:

: This study was approved by the ethics committees of Beijing No.6 hospital.

: The authors declare no competing interests.

Document is current